David Arthur

The Fort Worth oncology company tapped former Salarius Pharmaceuticals CEO David Arthur to lead its push toward commercialization, including a planned IND for a rare pediatric brain cancer program.

NanOlogy Names CEO as Its Tumor-Targeted Cancer Drugs Near Key Regulatory Milestones

by | Dec 30, 2025
The Fort Worth oncology company tapped former Salarius Pharmaceuticals CEO David Arthur to lead its push toward commercialization, including a planned IND for a rare pediatric brain cancer program.
MORE►
A Special Thank you to our sponsors

Dallas Innovates is owned by the Dallas Regional Chamber. Editorial operations are led independently by Lawley Head Media.

© Copyright 2026 | All rights reserved.

Business

Creative

Education

Impact

Invention

Startup

Our Sponsors

Our Partners